CBG Atlas

Safety & reporting
AtlasComparisonsCBDV vs THCV: Same Formula, Different Record
How we grade evidenceGlossaryCBG Monograph
Side by side

CBDV vs THCV: Same Formula, Different Record

On a chemistry slide, CBDV and THCV look like twins: both three-carbon "varin" cannabinoids, both C₁₉H₂₆O₂. Open the research record and the likeness falls apart. CBDV is non-intoxicating; what THCV does to the head shifts with dose. CBDV went through a proper clinical trial and missed its primary endpoint. THCV's best-known claim, appetite suppression, has no primary evidence in people. Established

For anyone buying or formulating with varins, the pair is a lesson in how little a shared formula predicts. One of them has been put to a fair test and came up short; the other is sold hardest on a claim with no primary human evidence behind it.

Every statement below is graded by the evidence behind it. Legal notes are general, dated and not legal advice; this page makes no therapeutic claim for either compound.

Side by side

AttributeCBDV — cannabidivarinTHCV — tetrahydrocannabivarin
Varin form ofCBDV — cannabidivarinCBDTHCV — tetrahydrocannabivarinTHC
Molecular formulaCBDV — cannabidivarinC₁₉H₂₆O₂ (CAS 24274-48-4)THCV — tetrahydrocannabivarinC₁₉H₂₆O₂ (CAS 31262-37-0)
Intoxicating?CBDV — cannabidivarinNo · EstablishedTHCV — tetrahydrocannabivarinDose-dependent (Pertwee 2008) · Demonstrated · in vitro
Best-known claimCBDV — cannabidivarinSeizures: a Phase 2 trial missed its primary endpoint (Brodie 2021) · Not supportedTHCV — tetrahydrocannabivarinAppetite: no primary evidence from any human study · No primary evidence
US legal status (general, dated; not legal advice)CBDV — cannabidivarinHemp-derived material is generally legal federally at ≤0.3% Δ⁹-THC; not FDA-approved as a food or supplementTHCV — tetrahydrocannabivarinComplicated by changing total-THC rules; varies by state
Figure P · targets side by side
CBDV and THCV at six targets: what our registry records, and where it records nothing
Six receptor and channel nodes in rows, with one column for CBDV and one for THCV. At CB1 cannabinoid receptor: CBDV has no graded interaction in our registry; THCV blocks, and at higher doses activates (direction reverses with dose; in a review, no rung of its own; Pertwee 2008). At CB2 cannabinoid receptor: CBDV has no graded interaction in our registry; THCV activates (partial agonist; an earlier paper reports the opposite; in a review, no rung of its own; Pertwee 2008). At α2-adrenoceptor: CBDV has no graded interaction in our registry; THCV has no graded interaction in our registry. At 5-HT1A serotonin receptor: CBDV has no graded interaction in our registry; THCV has no graded interaction in our registry. At TRPV1 and TRPV2 ion channels: CBDV has no graded interaction in our registry; THCV has no graded interaction in our registry. At TRPM8 ion channel: CBDV has no graded interaction in our registry; THCV has no graded interaction in our registry. CBDV: no receptor-level record in our registry at any of the six targets; the registry is CBG-centred. Every recorded direction was measured in receptors, cells or tissue, or is quoted from a review; none is an effect in people, and none is a dose.How to read a cellblocksactivatesactivates, then desensitisesdamps activationrecorded in a review, direction qualified by the source, no rung of its ownno graded interaction in our registryCBDVCannabidivarinTHCVTetrahydrocannabivarinCB1CBDV: no graded interactionin our registrya gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its ownTHCV blocks, and at higher doses activatesdirection reverses with dosein a review, no rung of its own · Pertwee 2008CB2CBDV: no graded interactionin our registrya gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its ownTHCV activatespartial agonist; an earlier paper reports the oppositein a review, no rung of its own · Pertwee 2008α2-adrenoceptorCBDV: no graded interactionin our registryTHCV: no graded interactionin our registry5-HT1ACBDV: no graded interactionin our registryTHCV: no graded interactionin our registryTRPV1 · TRPV2CBDV: no graded interactionin our registryTHCV: no graded interactionin our registryTRPM8CBDV: no graded interactionin our registryTHCV: no graded interactionin our registryCBDV: no receptor-level record in our registry at any of these six targets.The registry is CBG-centred, and an empty column shows that rather than hides it. Absence of a record is not evidence of no interaction.
How to read a cell
An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
CB1 cannabinoid receptor
CBDV: no graded interaction in our registry. THCV: blocks, and at higher doses activates (direction reverses with dose), in a review, no rung of its own study type: Review Pertwee 2008.
CB2 cannabinoid receptor
CBDV: no graded interaction in our registry. THCV: activates (partial agonist; an earlier paper reports the opposite), in a review, no rung of its own study type: Review Pertwee 2008.
α2-adrenoceptor
CBDV: no graded interaction in our registry. THCV: no graded interaction in our registry.
5-HT1A serotonin receptor
CBDV: no graded interaction in our registry. THCV: no graded interaction in our registry.
TRPV1 and TRPV2 ion channels
CBDV: no graded interaction in our registry. THCV: no graded interaction in our registry.
TRPM8 ion channel
CBDV: no graded interaction in our registry. THCV: no graded interaction in our registry.
A gold frame is a direction the registry holds only through a review, quoted with the qualification the source itself attaches; it carries no rung of its own. A dashed frame means the registry holds no graded interaction there, which is not the same as evidence of none. None of this is an effect in people, and none of it is a dose. CBDV has no receptor-level record in our registry at any of the six targets: the registry is CBG-centred, and the empty column says so. Sources: Pertwee 2008. CBG's record at researcher depth is on the monograph's target map; the receptors themselves are drawn on the ECS map →

The settled facts

The chemistry is the easy part. The harder facts sit further down, where the clinical claims are.

  • One formula, two molecules. Both are C₁₉H₂₆O₂. CBDV is the propyl homolog of CBD, THCV the propyl homolog of THC. Established
  • Intoxication. CBDV leaves the head clear. THCV is harder to pin down: in animals it behaves as a CB₁ antagonist, and at higher doses as an agonist (Pertwee 2008). Demonstrated · in vitro
  • CBDV for seizures was tested and failed. A Phase 2 randomised controlled trial enrolled adults with focal seizures. Seizures fell in both arms, and CBDV showed no separation from placebo on any seizure measure (Brodie 2021). Not supported
  • CBDV in autism has never been judged on symptoms. Both published human studies of CBDV in autism gave one dose and imaged the brain (Pretzsch 2019; Pretzsch 2021). Symptoms were outside what either set out to measure. No primary evidence
  • THCV and appetite. For the claim that sells THCV, our registry holds no primary evidence that it alters appetite or body weight in people. No primary evidence

Common questions

Are CBDV and THCV the same thing?

They are two different molecules that happen to share a formula, C₁₉H₂₆O₂. CBDV is the three-carbon counterpart of CBD and THCV the three-carbon counterpart of THC, and each takes after its parent more than its twin: the two act differently. Established

Does CBDV or THCV get you high?

CBDV doesn't; with THCV, it depends on the dose. Animal work shows it acting as a CB₁ antagonist and switching to an agonist at higher doses (Pertwee 2008). Where that tipping point sits in a person is anyone's guess, since no threshold for intoxication has been established in people. Demonstrated · in vitro

Does CBDV help with seizures?

No, and it had a fair chance to show otherwise. In a Phase 2 randomised controlled trial of adults with focal seizures, CBDV performed no better than placebo on any seizure measure (Brodie 2021). CBDV is no replacement for prescribed medication. Not medical advice. Not supported

Does THCV suppress appetite?

No published human study shows that it does. THCV is sold as "diet weed", yet no primary evidence shows that it changes appetite or body weight in a person. The nickname has outrun the data, and a label that leans on it is standing on air. Not medical advice. No primary evidence

Has CBDV been tested for autism?

Only in brain-imaging studies, which ask a different question from whether it helps. The two published human studies of CBDV in autism each gave a single dose and recorded brain signals rather than symptoms (Pretzsch 2019; Pretzsch 2021). Not medical advice. No primary evidence

Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.

Sources

  • Brodie et al. (2021). A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. PMID 33998885.
  • Pertwee et al. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. PMID 17828291.
  • Pretzsch et al. (2019). Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. Transl Psychiatry. PMID 31748505.
  • Pretzsch et al. (2021). Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. Mol Autism. PMID 34210360.

Before you act on what you have read

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →

Keep exploring

More comparisons